CEMACABTAGENE ANSEGEDLEUCEL
UNII W3X22HS7XD

Substance Identification & Data

This profile provides standardized clinical and technical data for Cemacabtagene Ansegedleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) W3X22HS7XD.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
W3X22HS7XD
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
CEMACABTAGENE ANSEGEDLEUCEL
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C172708
National Cancer Institute reference terminology for clinical and research data.
INN ID
12556
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
ITIS TSN
180092
Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.
NCBI Taxonomy
9606
Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cemacabtagene Ansegedleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CEMACABTAGENE ANSEGEDLEUCEL

Common Names & Synonyms

ALLOGENEIC T LYMPHOCYTES OBTAINED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS BY LEUKAPHERESIS OF HEALTHY VOLUNTEER DONORS, TRANSDUCED WITH A SELF-INACTIVATING, NON-REPLICATING LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING HUMAN CD19. THE CELLS ARE ALSO GENETICALLY MODIFIED USING TRANSCRIPTION ACTIVATOR-LIKE (TAL) EFFECTOR NUCLEASES THAT ARE TRANSIENTLY DELIVERED INTO THE CELL AS MRNAS VIA ELECTROPORATION AND CODE FOR TWO PAIRS: ONE PAIR IS DESIGNED FOR DISRUPTION OF THE T-CELL RECEPTOR ALPHA CONSTANT (TRAC) AND THE OTHER FOR DISRUPTION OF THE CD52 LOCUS
CEMACABTAGENE ANSEGEDLEUCEL [INN]
CEMACABTAGENE ANSEGEDLEUCEL [WHO-DD]

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus